Hannah Kesler
Psychiatric/Mental Health · Birmingham, ALNPI 1255805099
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 470 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 470 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Johnson & Johnson$1K
- Alkermes, Inc.$962
- Otsuka America Pharmaceutical, Inc.$941
- AbbVie$802
- Lundbeck LLC$666
- plus $3K from 18 others
What the payments were for
- Food & beverage$9,25898%
- Education$1662%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 76 | $1,483 |
| Johnson & Johnson | 46 | $1,228 |
| Alkermes, Inc. | 44 | $962 |
| Otsuka America Pharmaceutical, Inc. | 38 | $941 |
| AbbVie | 65 | $802 |
| Lundbeck LLC | 31 | $666 |
| Teva Pharmaceuticals USA, Inc. | 25 | $519 |
| Vanda Pharmaceuticals Inc. | 20 | $500 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $442 |
| Corium, LLC | 18 | $346 |
| Neurocrine Biosciences, Inc. | 17 | $275 |
| Ironshore Pharmaceuticals Inc. | 18 | $254 |
| Supernus Pharmaceuticals, Inc. | 14 | $194 |
| Axsome Therapeutics, Inc. | 8 | $178 |
| Indivior Inc. | 6 | $120 |
| Neuronetics, Inc. | 1 | $119 |
| E.r. Squibb & Sons, L.L.C. | 5 | $113 |
| Neos Therapeutics, LP | 4 | $83 |
| Tris Pharma Inc | 4 | $69 |
| Almatica Pharma LLC | 3 | $66 |
| Noven Therapeutics, LLC | 1 | $24 |
| Adlon Therapeutics L.p. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$461
- LYBALVI$459
- SPRAVATO$125
- REXULTI$121
- NEUROSTAR TMS THERAPY$119
- ARISTADA INITIO$115
How this compares
$9,424 in reported general payments places this provider in the 90th percentile of 378 psychiatric/mental health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 58 | $78,818 |
| RexultiBrexpiprazole | 40 | $58,333 |
| Aripiprazole | 84 | $7,235 |
| Duloxetine Hcl | 96 | $2,839 |
| Doxepin Hcl | 29 | $2,382 |
| Vilazodone Hcl | 21 | $1,957 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 32 | $1,660 |
| Haloperidol | 26 | $1,231 |
| Trazodone Hcl | 127 | $1,212 |
| Buspirone Hcl | 102 | $1,141 |
| Quetiapine Fumarate | 100 | $1,139 |
| Bupropion XlBupropion Hcl | 52 | $1,106 |
| Ziprasidone Hcl | 14 | $990 |
| Escitalopram Oxalate | 129 | $922 |
| Hydroxyzine Hcl | 42 | $920 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $802 | $78,81858 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $941 | $58,33340 claims |
| Almatica Pharma LLCSertraline Hcl | $66 | $42173 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 378 psychiatric/mental health providers in Alabama.
Other psychiatric/mental health in Birmingham
- Yuliya SpencerBirmingham$65K
- David CoffmanBirmingham$13K
- Tiffany WallerBirmingham$12K
- Kellie VaughnBirmingham$12K
- Amanda BoydBirmingham$10K
- Judy ClarkBirmingham$9K
- Jessica AdwellBirmingham$9K
- Pamela Kite TrullBirmingham$9K
- Lacey PodyBirmingham$7K
- Emily MartinBirmingham$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.